Tecentriq Wins Approval

The U.S. Food and Drug Administration approved Roche’s new immunotherapy drug Tecentriq to be used in non-small cell lung cancer patients previously treated with chemotherapy. Read article here…..

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.